Austco Healthcare (AHC) Q1 2025 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 TU earnings summary
19 Aug, 2026Executive summary
Organic revenues grew 16% year-over-year in Q1 FY25, with total revenue up 90% including recent acquisitions.
Major contract wins included a $5.0 million deal for Surrey Hospital and an expanded $5.5 million Jurong Health Complex contract.
Record contracted orders reached $51.1 million, reflecting strong demand and execution of growth strategy.
Financial highlights
Q1 FY25 organic revenue increased 16% compared to the prior corresponding period.
Including Teknocorp and Amentco, total revenue rose 90% year-over-year.
Contracted orders hit a record $51.1 million as of October 2024.
Outlook and guidance
Positioned for continued growth through enhanced sales and marketing in high-growth markets.
Focus remains on executing growth-driven strategies to deliver long-term shareholder value.
Latest events from Austco Healthcare
- Record revenue, profit, and recurring software growth, with strong cash and major contract wins.AHC
H2 2026 - Record revenue and profit growth driven by contracts, acquisitions, and software innovation.AHC
Investor presentation - Record revenue, profit, and software growth driven by acquisitions and innovation.AHC
Investor presentation - Record revenue and EBITDA growth, global expansion, and strong cash position drive future outlook.AHC
Investor presentation - Record revenue and profit growth, with strong order backlog and positive growth outlook.AHC
H2 2024 - First-half FY25 revenue and EBITDA are set to surge, boosted by acquisitions and organic growth.AHC
Q2 2025 TU - Record revenue and EBITDA growth, strong profit, and robust order book support future performance.AHC
H1 2025 - Revenue and EBITDA surged year-over-year, with strong cash flow and robust contracted revenue.AHC
Q4 2025 TU - Record revenue and EBITDA growth, strong cash, and robust orders position for continued expansion.AHC
H2 2025